{"id":238198,"date":"2026-06-02T14:03:21","date_gmt":"2026-06-02T19:03:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/breakthrough-cholesterol-cure-lowers-ldl-for-life"},"modified":"2026-06-02T14:03:21","modified_gmt":"2026-06-02T19:03:21","slug":"breakthrough-cholesterol-cure-lowers-ldl-for-life","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/breakthrough-cholesterol-cure-lowers-ldl-for-life","title":{"rendered":"BREAKTHROUGH CHOLESTEROL CURE Lowers LDL For Life"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/8CD5RA9yXQ0?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well\u2026 the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart disease. The science is real. The hype is getting ahead of what the paper actually says. This episode walks through the Phase 1 Heart-2 trial \u2014 the data, the base-editing mechanism (which is NOT CRISPR), the one safety event nobody\u2019s talking about, and how Eli Lilly\u2019s CEO is publicly thinking about pricing a one-and-done cure.<\/p>\n<p>HUME BODY POD DISCOUNT UP TO 50% OFF:<br \/> Code: LSN20<br \/>\n<a href=\"https:\/\/humehealth.com\/pages\/hume-bod\">https:\/\/humehealth.com\/pages\/hume-bod<\/a>\u2026 Latte: <a href=\"https:\/\/longevitylatte.shop\">https:\/\/longevitylatte.shop<\/a> TIMESTAMPS 0:00 \u2014 Cold Open 1:41 \u2014 Sponsor: Hume Body Pod 2:53 \u2014 Intro: The Cholesterol Paradox 4:48 \u2014 How Statins Work 5:36 \u2014 PCSK9 Targeting 7:38 \u2014 How VERVE-102 Works 9:16 \u2014 The Results 12:16 \u2014 Other Drugs and Pricing 15:12 \u2014 Natural Alternatives 17:42 \u2014 Other One and Done Drugs 18:40 \u2014 Longevity Latte SOURCES &amp; LINKS NEJM paper (Vafai, T\u00e4ubel, Patel, Kathiresan et al.): <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\">https:\/\/www.nejm.org\/doi\/full\/10.1056<\/a>\u2026 Eli Lilly press release on Phase 1 Heart-2 data: <a href=\"https:\/\/www.prnewswire.com\/news-relea\">https:\/\/www.prnewswire.com\/news-relea<\/a>\u2026 ClinicalTrials.gov Heart-2 trial entry (NCT06164730): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT0\">https:\/\/clinicaltrials.gov\/study\/NCT0<\/a>\u2026 Verve Therapeutics FDA Fast Track designation announcement: <a href=\"https:\/\/vervetx.gcs-web.com\/news-rele\">https:\/\/vervetx.gcs-web.com\/news-rele<\/a>\u2026 Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): <a href=\"https:\/\/www.nejm.org\/doi\/abs\/10.1056\/.\">https:\/\/www.nejm.org\/doi\/abs\/10.1056\/.<\/a>\u2026 Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: <img alt=\"\" class=\"\"> \u2022 Dave Ricks, CEO of Eli Lilly, on GLP-1s an\u2026 FOURIER trial (evolocumab cardiovascular outcomes): <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\">https:\/\/www.nejm.org\/doi\/full\/10.1056<\/a>\u2026 ODYSSEY OUTCOMES trial (alirocumab cardiovascular outcomes): <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\">https:\/\/www.nejm.org\/doi\/full\/10.1056<\/a>\u2026 PCSK9 LoF and diabetes (Mendelian randomization, Lancet Diabetes &amp; Endocrinology): <a href=\"https:\/\/www.thelancet.com\/journals\/la\">https:\/\/www.thelancet.com\/journals\/la<\/a>\u2026 PCSK9 inhibition and diabetes risk review: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles<\/a>\u2026 StatPearls overview of PCSK9 inhibitors: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NB\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NB<\/a>\u2026 Sardinia cholesterol paradox study: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles<\/a>\u2026 Statin pleiotropic effects review (mevalonate pathway): <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/arti\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/arti<\/a>\u2026 Berberine as a nature-made PCSK9 inhibitor review: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/arti\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/arti<\/a>\u2026 Berberine for dyslipidaemias meta-analysis: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30466\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30466<\/a>\u2026 Pomegranate juice, carotid IMT, and LDL oxidation (Aviram 3-year study): <a href=\"https:\/\/www.clinicalnutritionjournal\">https:\/\/www.clinicalnutritionjournal<\/a>\u2026 LATEST EXCLUSIVE INTERVIEW: [Ariel Garten \/ Muse headset interview YouTube URL] ABOUT LONGEVITY SCIENCE NEWS Longevity Science News covers the latest breakthroughs in anti-aging research, regenerative medicine, longevity biotech, and the science of extending human healthspan and lifespan. Hosted by Emmett Short. Disclaimer: This video is for educational and informational purposes only and does not constitute medical advice. Consult a qualified clinician before making health or treatment decisions. EXCLUSIVE INTERVIEWS &amp; BONUS CONTENT Patreon: <a href=\"https:\/\/patreon.com\/u29506604?utm_med\">https:\/\/patreon.com\/u29506604?utm_med<\/a>\u2026 YT Membership: <img alt=\"\" class=\"\"> \/ <a href=\"https:\/\/twitter.com\/longevitysciencenews\">@longevitysciencenews<\/a> PRODUCTION CREDITS Executive Producer \u2013 Keith Comito Host, Producer, Writer \u2013 Emmett Short.<\/p>\n<p>Longevity Latte:<br \/>\n<a href=\"https:\/\/longevitylatte.shop\">https:\/\/longevitylatte.shop<\/a>.<\/p>\n<p>TIMESTAMPS<br \/> 0:00 \u2014 Cold Open.<br \/> 1:41 \u2014 Sponsor: Hume Body Pod.<br \/> 2:53 \u2014 Intro: The Cholesterol Paradox.<br \/> 4:48 \u2014 How Statins Work.<br \/> 5:36 \u2014 PCSK9 Targeting.<br \/> 7:38 \u2014 How VERVE-102 Works.<br \/> 9:16 \u2014 The Results.<br \/> 12:16 \u2014 Other Drugs and Pricing.<br \/> 15:12 \u2014 Natural Alternatives.<br \/> 17:42 \u2014 Other One and Done Drugs.<br \/> 18:40 \u2014 Longevity Latte.<\/p>\n<p>SOURCES \\&amp; LINKS<br \/> NEJM paper (Vafai, T\u00e4ubel, Patel, Kathiresan et al.): <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\">https:\/\/www.nejm.org\/doi\/full\/10.1056<\/a>\u2026<br \/> Eli Lilly press release on Phase 1 Heart-2 data: <a href=\"https:\/\/www.prnewswire.com\/news-relea\">https:\/\/www.prnewswire.com\/news-relea<\/a>\u2026<br \/> ClinicalTrials.gov Heart-2 trial entry (NCT06164730): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT0\">https:\/\/clinicaltrials.gov\/study\/NCT0<\/a>\u2026<br \/> Verve Therapeutics FDA Fast Track designation announcement: <a href=\"https:\/\/vervetx.gcs-web.com\/news-rele\">https:\/\/vervetx.gcs-web.com\/news-rele<\/a>\u2026<br \/> Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): <a href=\"https:\/\/www.nejm.org\/doi\/abs\/10.1056\/.\">https:\/\/www.nejm.org\/doi\/abs\/10.1056\/.<\/a>\u2026<br \/> Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: \u2022 Dave Ricks, CEO of Eli Lilly, on GLP-1s an\u2026<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well\u2026 the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,32,269],"tags":[],"class_list":["post-238198","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-education","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=238198"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238198\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=238198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=238198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=238198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}